Genetic Technologies Company Insiders

Genetic Technologies Management Team Effectiveness

The company has return on total asset (ROA) of (0.5271) % which means that it has lost $0.5271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6047) %, meaning that it created substantial loss on money invested by shareholders. Genetic Technologies' management efficiency ratios could be used to measure how well Genetic Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -1.26. In addition to that, Return On Capital Employed is expected to decline to -1.04. At present, Genetic Technologies' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 10.6 M, whereas Total Current Assets are forecasted to decline to about 11.7 M. The current year's Common Stock Shares Outstanding is expected to grow to about 122.4 M, whereas Net Loss is forecasted to decline to (11.1 M).

Genetic Technologies Workforce Comparison

The company has Profit Margin (PM) of (1.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.06.

Genetic Technologies Insider Trading

Genetic Technologies Notable Stakeholders

The success or failure of an entity such as Genetic Technologies often depends on how effective the management is. Genetic Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Genetic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Genetic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in Genetic Technologies' official financial statements usually reflect Genetic Technologies' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Genetic Technologies. For example, before you start analyzing numbers published by Genetic accountants, it's critical to develop an understanding of what Genetic Technologies' liquidity, profitability, and earnings quality are in the context of the Life Sciences Tools & Services space in which it operates.

Please note, the presentation of Genetic Technologies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genetic Technologies' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Genetic Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Genetic Technologies. Please utilize our Beneish M Score to check the likelihood of Genetic Technologies' management manipulating its earnings.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.

Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.